SHENZHEN, CHINA and ROCKVILLE, MD, October 10, 2019 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced that multiple abstracts for HTD1801...

HighTide Therapeutics (“HighTide”) and Silexon Tech (“Silexon”) jointly announced a long-term strategic collaboration agreement in new drug research and development.

Based on Safety Data Review, DMC Recommends Continuing Trial

SHENZHEN, CHINA and ROCKVILLE, MD, July 11, 2019 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced that it has become a resident company at JLABS @ Shanghai.

SHENZHEN, CHINA and ROCKVILLE, MD, July 02, 2019 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced that Adrian M. Di Bisceglie, M.D., has been appointed as Chief Medical Officer.

HighTide Therapeutics is proud to sponsor the annual PSC patient advocacy conference organized by PSC Partners Seeking a Cure. This year the annual conference will take place June 21-23 in Rochester, Minnesota in partnership with Mayo Clini